公費疫苗 肺炎鏈球菌疫苗 Pneumococcal vaccines are indicated for the prevention of serious pneumococcal infections in patients at high risk for pneumococcal disease such as patients with splenectomy, sickle-cell anemia, nephrotic syndrome, and chronic illnesses such as cardiovascular or chronic obstructive pulmonary disease, and patients 50 years of age or older.

N/A

Peak Response : 2 to 6 weeks.
Duration :
General antibody titers: 5 to 8 years Strep pneumoniae: 1 to 2 years

Anaphylactic/anaphylactoid or severe allergic reaction to any component of the pneumococcal vaccine

C(FDA) B2(AUS)

Micromedex Lactation Rating: Infant risk is minimal.
The weight of an adequate body of evidence and/or expert consensus suggests this drug poses minimal risk to the infant when used during breastfeeding.

Clinical Management
Currently, there is no data on the administration of pneumococcal vaccine while breastfeeding. The effect of maternal vaccination on the nursing infant is unknown. According to the American Advisory Committee on Immunization Practices, breastfeeding women may be immunized with both live and killed vaccines [76]. Vaccines, in general, are considered safe for use in breastfeeding women [77].

Frequency not defined.
Cardiovascular: Peripheral edema (in injected extremity)
Central nervous system: Chills, Guillain-Barr? syndrome, febrile seizures, headache, malaise, pain, paresthesia, radiculopathy
Dermatologic: Cellulitis, skin rash, urticaria
Gastrointestinal: Nausea, vomiting
Hematologic & oncologic: C-reactive protein increased, hemolytic anemia (in patients with other hematologic disorders), leukocytosis, lymphadenitis, lymphadenopathy, thrombocytopenia (in patients with stabilized immune thrombocytopenia [formerly known as idiopathic thrombocytopenic purpura])
Hypersensitivity: Anaphylactoid reaction, angioedema, serum sickness
Local: Injection site reaction (most common in clinical trials; includes erythema at injection site, induration at injection site, local soreness/soreness at injection site, swelling at injection site, warm sensation at injection site)
Neuromuscular & skeletal: Arthralgia, arthritis, decreased range of motion (limb), myalgia, weakness
Miscellaneous: Fever (most common in clinical trials: ?102°F; fever >102°F)

Adults: 0.5 ml IM or SC for adults and children age 2 and older; a single dose is effective. Do not administer intravenously or intradermally.

Children: 0.5 ml of the polyvalent vaccine SC or IM for pneumococcal prophylaxis; pneumococcal vaccine may be administered at the same time as influenza vaccine (by separate injection in the other arm)

N/A

N/A

Vials left at room temperature inadvertently can be refrigerated again without loss of potency if the period of time at room temperature does not exceed 72 hours. A one-time exposure to freezing temperatures does not alter the antigenicity of the vaccine.